Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LOXL2 | Q9Y4K0 | 4/20 | 0.36 |
| ▸ | LOX | P28300 | 2/20 | 0.36 |
| ▸ | NUDT1 | P36639 | 3/20 | 0.34 |
| ▸ | MBOAT4 | Q96T53 | 1/20 | 0.33 |
| ▸ | NOS3 | P29474 | 1/20 | 0.32 |
| ▸ | NOS1 | P29475 | 1/20 | 0.32 |
| ▸ | NOS2 | P35228 | 1/20 | 0.32 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23767530 | 0.83 | MBOAT4 (0.38) | LOXL2LOXNUDT1MBOAT4NOS3 | |
| SCHEMBL2032467 | 0.76 | NUDT1 (0.49) | NUDT1 | |
| SCHEMBL1509561 | 0.76 | LOXL2 (0.52) | LOXL2LOXMBOAT4NOS3NOS2 | |
| SCHEMBL3511885 | 0.72 | LOXL2 (0.52) | LOXL2LOXNUDT1NOS3NOS1 | |
| SCHEMBL4883101 | 0.72 | CCR1 (0.36) | NUDT1NOS3NOS1NOS2 | |
| SCHEMBL5345094 | 0.72 | NUDT1 (0.30) | NUDT1 | |
| SCHEMBL750287 | 0.69 | CCNT1 (0.38) | — | |
| SCHEMBL4399077 | 0.69 | SYK (0.37) | — | |
| SCHEMBL1509571 | 0.69 | — | — | |
| SCHEMBL30402790 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8809358-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2014-08-19 | — | — | US | disclosed |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2009-03-12 | — | — | US | disclosed |
| EP-1531819-B1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | SANOFI AVENTIS DEUTSCHLAND (DE) | 2008-12-24 | — | — | EP | disclosed |
| US-7462638-B2 | Use of IκB-kinase inhibitors in pain therapy | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2008-12-09 | — | — | US | disclosed |
| US-20080015353-A1 | PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF | AJINOMOTO CO., INC. (JP) | 2008-01-17 | — | — | US | disclosed |
| EP-1849761-A1 | PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF | Ajinomoto Co., Inc. (JP) | 2007-10-31 | — | — | EP | disclosed |
| US-20070142417-A1 | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor | AVENTIS PHARMACEUTICALS INC (US) | 2007-06-21 | — | — | US | disclosed |
| EP-1747215-A1 | SUBSTANTIALLY PURE 2-{¬2-(2-METHYLAMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBONYL|-AMINO}-3-(PHENYLPYRIDIN-2-YL-AMINO)-PROPIONIC ACID AS AN IKB KINASE INHIBITOR | Aventis Pharmaceuticals, Inc. (US) | 2007-01-31 | — | — | EP | disclosed |
| WO-2005113544-A1 | SUBSTANTIALLY PURE 2-{[2-(2-METHYLAMINO-PYRIMIDIN-4-YL)-1H-INDOLE-5-CARBONYL]-AMINO}-3-(PHENYLPYRIDIN-2-YL-AMINO)-PROPIONIC ACID AS AN IKB KINASE INHIBITOR | AVENTIS PHARMACEUTICALS INC. (US) | 2005-12-01 | — | — | WO | disclosed |
| EP-1531819-A1 | USE OF I kappa B KINASE INHIBITORS FOR THE TREATMENT OF PAIN | Aventis Pharma Deutschland GmbH (DE) | 2005-05-25 | — | — | EP | disclosed |
| US-20040116494-A1 | Use of IkappaB-kinase inhibitors in pain therapy | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-06-17 | — | — | US | disclosed |
| WO-2004022057-A1 | USE OF IκB KINASE INHIBITORS FOR THE TREATMENT OF PAIN | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2004-03-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080015353-A1 | PROCESS FOR PRODUCTION OF 4-ACETYLPYRIMIDINES AND CRYSTALS THEREOF | DPYD, UMPS, PNPO | LOXL2 1765/4885LOX 233/4885NUDT1 13/4885 |
| US-20090069358-A1 | Use of IKappaB-Kinase Inhibitors in Pain Therapy | NFKBIA, IKBKB, IKBKE | LOXL2 3597/4885LOX 1582/4885NUDT1 3375/4885 |
| US-20070142417-A1 | Substantially Pure 2-{[2-(2-Methylamino-Pyrimidin-4-YL)-1H-Indole-5-Carbonyl]-Amino}-3-Phenylpyridin-2-YL-Amino)-Propionic Acid as an IkB Kinase Inhibitor | IKBKB, NFKBIA, IKBKG | LOXL2 1487/4885LOX 1507/4885NUDT1 4206/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.